This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Zogenix To Present SUMAVEL(R) DosePro(TM) Phase 4 Results At American Academy Of Neurology

Stocks in this article: ZGNX

SAN DIEGO, March 1, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced that data from a Phase 4 clinical study of SUMAVEL ® DosePro™ (sumatriptan injection) Needle-free Delivery System will be presented in two posters at the 63 rd Annual Meeting of the American Academy of Neurology (AAN), to be held April 9 – 16, 2011 at the Hawaii Convention Center, Honolulu, HI. A summary of the Company's AAN presentations is below, and the abstracts can be accessed at the AAN website at www.aan.com .

The Phase 4 open-label, multicenter U.S. study evaluated overall satisfaction, confidence and preference for SUMAVEL DosePro in treating multiple migraine attacks in more than 200 adult patients diagnosed with migraine and currently taking triptan therapy. Efficacy, including onset and sustained duration of pain relief/freedom from pain, and tolerability of therapy with SUMAVEL DosePro were also measured.

Title: Improved Treatment Satisfaction and Confidence Among Current Triptan Users Trying SUMAVEL® DosePro™ (needle-free subcutaneous sumatriptan) for Up to 4 Migraine Attacks
Authors: Cady R, Aurora SK, Brandes JL, Rothrock J, Myers JA, Fox AW, Farr SJ
Date & Time: Wednesday, April 13, 2011; 2:00PM – 6:00PM
Poster Number: NO P05.275
   
   
Title: Multiple-Attack Efficacy and Tolerability of SUMAVEL ® DosePro™ (needle-free subcutaneous sumatriptan) Among Current Triptan Users
Authors: Brandes JL, Rothrock J, Cady R, Aurora SK, Myers JA, Fox AW, Farr SJ
Date & Time: Wednesday, April 13, 2011; 2:00PM – 6:00PM
Poster Number: NO P05.283

Zogenix and its co-promotion partner, Astellas Pharma US, Inc., launched SUMAVEL DosePro in the United States in January 2010 for the acute treatment of migraine and cluster headache.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs